⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 5, 2024Journal of the National Comprehensive Cancer Network

CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer

John Sharp Daniel Jones Julia Rotow Panos Fidias Erin M. Bertino Dwight H. Owen

View at Publisher

Ask AI

Bookmark

Share

Abstract

"CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer" published on 05 Apr 2024 by National Comprehensive Cancer Network.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sharp et al. (2024) studied this question.

synapsesocial.com/papers/68e70542b6db64358767eb8b https://doi.org/10.6004/jnccn.2023.7312

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer2024 · 2 citations
2Response to <scp>dabrafenib</scp> plus trametinib on a rare <scp>BRAF</scp> mutation (<scp>V600_W604</scp> deletion–insertion <scp>R</scp>) in an advanced non‐small cell lung cancer patient2024 · 2 citations
3Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience2024 · 5 citations
4Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib2024 · 1 citations
5Dabrafenib and trametinib in patients with tumors with <i>BRAF V600E/k</i> mutations: Updated results from NCI-MATCH arm H.2024 · 1 citations